Trulieve Cannabis Corp. Subordi (TRLV) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.11

Estimate

$0.03

Surprise

+266.7%

Revenue (period 2026-06-30)

$271.0M

Score at report (before → after)

5.8 → 5.7/10

Revenue source: xbrl.

Trulieve Cannabis Corp. Subordi (TRLV) beat the $0.03 estimate with diluted EPS of $0.11 — a large 266.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Hold at 5.7/10 after the report — the engine's score fell despite the beat.

TrendMatrix currently rates TRLV Hold at 5.8/10.

2 of the last 4 quarters beat the estimate; this quarter's +266.7% surprise compares with a +148.6% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$11.09

Price target

$15.82

Stop

$10.32

Upside to target

+42.7%

Reward-to-risk

2.8:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$2.14B

P/E (fwd)

20.0

52-week range

$4.62–$13.28

Off 52-week high

16.5%

RSI (14)

77

Volume vs avg

1.71×

Score today

5.8/10